These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 23242113)

  • 21. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
    Galera C; Soohun N; Zankar N; Caimmi S; Gallen C; Demoly P
    J Investig Allergol Clin Immunol; 2009; 19(3):225-9. PubMed ID: 19610266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of omalizumab in allergen immunotherapy.
    Dantzer JA; Wood RA
    Clin Exp Allergy; 2018 Mar; 48(3):232-240. PubMed ID: 29315922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
    Ong YE; Menzies-Gow A; Barkans J; Benyahia F; Ou TT; Ying S; Kay AB
    J Allergy Clin Immunol; 2005 Sep; 116(3):558-64. PubMed ID: 16159624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omalizumab: not only for asthma.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unpredicted adverse reaction to omalizumab.
    Jandus P; Hausmann O; Haeberli G; Gentinetta T; Mueller U; Helbling A
    J Investig Allergol Clin Immunol; 2011; 21(7):563-6. PubMed ID: 22312942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-IgE therapy: clinical utility and mechanistic insights.
    Logsdon SL; Oettgen HC
    Curr Top Microbiol Immunol; 2015; 388():39-61. PubMed ID: 25553794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of therapy with omalizumab in children.
    Baena-Cagnani CE; Gómez RM
    Curr Opin Allergy Clin Immunol; 2014 Apr; 14(2):149-54. PubMed ID: 24535142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omalizumab and the immune system: an overview of preclinical and clinical data.
    Johansson SG; Haahtela T; O'Byrne PM
    Ann Allergy Asthma Immunol; 2002 Aug; 89(2):132-8. PubMed ID: 12197568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of severe asthma and peach allergy that improved with omalizumab therapy: a case report].
    Suzuki S; Matsuura T; Kimura T; Tazaki T; Fukuda M; Homma T; Matsukura S; Kurokawa M; Adachi M
    Arerugi; 2012 Feb; 61(2):215-23. PubMed ID: 22437731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
    Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
    BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
    Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
    Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.